Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
NDC Package 76282-678-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate is efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. Marketed by Exelan Pharmaceuticals, Inc., this product is identified by NDC 76282-678 and is authorized under FDA application ANDA206894.

Identification & Billing

NDC Package Code
76282-678-30
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
76282-678
11-Digit Billing Format
76282067830
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 643066 - efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
  • RxCUI: 643066 - efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet

Clinical Specifications

Proprietary Name
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Dosage Form
-
Usage Information
Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.

Regulatory & Marketing

Labeler Name
Exelan Pharmaceuticals, Inc.
FDA Application #
ANDA206894
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-30-2021
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76282-678-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate, labeled by Exelan Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Exelan Pharmaceuticals, Inc. on March 30, 2021. The current certification is valid through December 31, 2022.

How is this Exelan Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76282067830. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76282-678-30
11-Digit CMS (5-4-2)
76282-0678-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.